ResearchPP01.20: Integrating Clinicopathologic and Genomic Features to Identify Patients at Risk of Earlier Progression to First-Line Osimertinib in EGFR-Mutant NSCLC
ResearchPrognostic significance of STK11, KEAP1, and NFE2L2- mutations in lung squamous cell carcinoma treated with immunotherapy with or without chemotherapy
ResearchClinical significance of EGFR amplification in patients with EGFR -mutated metastatic non–small cell lung cancer receiving first-line osimertinib
ResearchIndefinite versus 2 years fixed duration of immune checkpoint inhibition in metastatic non–small cell lung cancer
ResearchTelehealth visits to support extended dosing of pembrolizumab and reduce health care visits: A pragmatic trial
ResearchCerebrospinal fluid biomarker profiling in patients with non–small cell lung cancer and leptomeningeal disease
ResearchA Phase 2 Basket Trial of Ado-Trastuzumab Emtansine for Patients with HER2 Amplified Cancers: A Non-Randomized Clinical Trial
ResearchUse of a large language model (LLM) for pan-cancer automated detection of anti-cancer therapy toxicities and translational toxicity research
ResearchOGCT-07 ICON-RT: A RANDOMIZED PHASE 2 TRIAL OF CONSOLIDATIVE STEREOTACTIC RADIOSURGERY (SRS) VERSUS CONTINUED OSIMERTINIB IN EGFR-MUTANT NSCLC PATIENTS WITH RESIDUAL BRAIN METASTASES FOLLOWING INITIAL TKI RESPONSE
ResearchLack of disease control remains a major barrier to transplant for relapsed/refractory acute myeloid leukemia: A single-institution experience
ResearchClinicogenomic analysis of EGFR-mutant lung tumors identifies Rb pathway inactivation as a hallmark of squamous transformation
ResearchClinical Significance of MTAP Deletions and Their Overlap With Concurrent Oncogenic Driver Alterations Including EGFR in NSCLC